trending Market Intelligence /marketintelligence/en/news-insights/trending/swt-5y8_bulroq9nz0prhw2 content esgSubNav
In This List

ProQR prices common stock offering

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


ProQR prices common stock offering

ProQR Therapeutics NV priced an underwritten public offering of 5,750,000 ordinary shares at $15.75 each.

The Netherlands-based biopharmaceutical company expects to raise gross proceeds of about $90.6 million through the offering, which is expected to close Sept. 11, subject to customary closing conditions.

Underwriters have a 30-day option to buy up to 862,500 additional ordinary shares at the offering price.

Citigroup, Evercore ISI and RBC Capital Markets are acting as joint book runners for the offering, with H.C. Wainwright & Co. and Chardan as co-managers. Kempen & Co. is acting as ProQR's European financial adviser for the offering.